Arcutis Biotherapeutics, Inc.

NasdaqGS:ARQT Stock Report

Market Cap: US$2.0b

Arcutis Biotherapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ARQT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 Mar 25SellUS$327,019Todd WatanabeIndividual25,015US$13.28
04 Mar 25SellUS$49,408Patrick BurnettIndividual3,773US$13.28
03 Mar 25SellUS$42,520Masaru MatsudaIndividual3,263US$13.03
03 Feb 25SellUS$153,873Patrick BurnettIndividual12,116US$12.70
03 Feb 25SellUS$27,597Larry EdwardsIndividual2,173US$12.70
03 Feb 25SellUS$105,893Masaru MatsudaIndividual8,338US$12.70
03 Feb 25SellUS$245,123Todd WatanabeIndividual19,301US$12.70
31 Dec 24SellUS$23,674Patrick BurnettIndividual1,691US$14.00
30 Nov 24BuyUS$18,543Masaru MatsudaIndividual5,657US$7.11
30 Nov 24BuyUS$21,250Todd WatanabeIndividual6,038US$7.11
30 Nov 24BuyUS$7,767Larry EdwardsIndividual1,093US$7.11
19 Nov 24SellUS$17,190Masaru MatsudaIndividual1,775US$9.68
14 Nov 24SellUS$522,436Patrick BurnettIndividual50,749US$10.29
11 Nov 24SellUS$94,238Terrie CurranIndividual8,687US$10.85
04 Nov 24SellUS$134,093Patrick BurnettIndividual15,441US$8.68
04 Nov 24SellUS$43,551Masaru MatsudaIndividual5,015US$8.68
04 Nov 24SellUS$120,459Todd WatanabeIndividual13,871US$8.68
02 Oct 24SellUS$37,295Larry EdwardsIndividual3,725US$10.01
24 Sep 24SellUS$110,264David TopperIndividual11,626US$9.48
03 Sep 24SellUS$107,695Howard WelgusIndividual10,000US$10.77
19 Aug 24SellUS$14,318Patrick BurnettIndividual1,728US$8.29
02 Aug 24SellUS$130,648Todd WatanabeIndividual14,487US$9.02
29 May 24SellUS$435,387Patrick BurnettIndividual49,952US$8.72
28 May 24SellUS$15,988Masaru MatsudaIndividual1,775US$9.01
17 May 24SellUS$68,582Larry EdwardsIndividual7,640US$8.98
02 May 24SellUS$40,902Matthew MooreIndividual4,681US$8.74

Insider Trading Volume

Insider Buying: ARQT insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ARQT?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,241,7661.68%
VC/PE Firms8,785,2846.59%
Hedge Funds22,365,81016.8%
Institutions99,920,37275%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 92.53% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
10.4%
Jennison Associates LLC
12,339,792US$209.9m5.8%0.12%
9.61%
Suvretta Capital Management, LLC
11,399,138US$193.9m6.32%6.79%
9.24%
Rubric Capital Management LP
10,966,672US$186.5m0%3.4%
7.71%
BlackRock, Inc.
9,148,490US$155.6m1.32%no data
7.41%
Frazier Life Sciences Management, LP
8,785,284US$149.4m0%5.8%
6.22%
Polar Capital Holdings Plc
7,377,381US$125.5m7.16%0.43%
5.43%
The Vanguard Group, Inc.
6,440,715US$109.6m-7.5%no data
4.17%
State Street Global Advisors, Inc.
4,950,725US$84.2m-12.3%no data
3.5%
Morgan Stanley, Investment Banking and Brokerage Investments
4,147,382US$70.5m10.3%0.01%
3.29%
Gilder Gagnon Howe & Co. LLC
3,902,991US$66.4m9.82%0.75%
2.79%
Franklin Resources, Inc.
3,308,975US$56.3m-22.2%0.02%
2.59%
UBS Asset Management AG
3,069,630US$52.2m518%no data
2.12%
D. E. Shaw & Co., L.P.
2,513,577US$42.8m44%0.05%
2.08%
Geode Capital Management, LLC
2,472,730US$42.1m0.1%no data
2%
Ensign Peak Advisors, Inc.
2,374,140US$40.4m-1.77%0.07%
1.95%
Millennium Management LLC
2,310,163US$39.3m101%0.03%
1.79%
Pivotal BioVenture Partners LLC
2,120,508US$36.1m0%13.21%
1.59%
Point72 Asset Management, L.P.
1,888,679US$32.1m664%0.07%
1.54%
Cormorant Asset Management, LP
1,825,000US$31.0m-21.5%1.98%
1.5%
Medical Strategy GmbH, Asset Management Arm
1,779,301US$30.3m0%1.69%
1.37%
American Century Investment Management Inc
1,631,226US$27.7m11.4%0.01%
1.3%
GW&K Investment Management, LLC
1,544,084US$26.3m-3.11%0.21%
1.06%
Cercano Management LLC
1,255,365US$21.4m0%0.53%
0.95%
Goldman Sachs Group, Investment Banking and Securities Investments
1,130,477US$19.2m-17.5%0.01%
0.92%
Driehaus Capital Management LLC
1,096,769US$18.7m27,700%0.11%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/23 07:45
End of Day Share Price 2025/03/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcutis Biotherapeutics, Inc. is covered by 13 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Chris ShibutaniGoldman Sachs
Seamus FernandezGuggenheim Securities, LLC
Douglas TsaoH.C. Wainwright & Co.